A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells

mAbs

Volumn 6, Issue 3, 2014, Pages 727-738

  Reusch, Uwe ^a   Burkhardt, Carmen ^a   Fucek, Ivica ^a   Le Gall, Fabrice ^a,b   Le Gall, Mikaelle ^a,c   Hoffmann, Karin ^a,d   Knackmuss, Stefan H J ^a   Kiprijanov, Sergej ^a,e   Little, Melvyn ^a   Zhukovsky, Eugene A ^a  

^a Affimed GmbH   (Germany)

^b Ganymed Pharmaceuticals AG   (Germany)

^c Ribological GmbH   (Germany)

^d INNOCOLL GmbH   (Germany)

^e BerGenBio   (Norway)

Author keywords

Bispecific antibodies; CD16A; Fc RIIIA; Hodgkin's lymphoma; NK cells

Indexed keywords

CD30 ANTIGEN; FC RECEPTOR; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; TETRAVALENT BISPECIFIC CD30 CD16A TANDEM DIABODY; UNCLASSIFIED DRUG; BISPECIFIC ANTIBODY; FCGR3A PROTEIN, HUMAN; IMMUNOGLOBULIN FRAGMENT; IMMUNOGLOBULIN FV; PEPTIDE LIBRARY;

ALLOTYPE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SCREENING; ARTICLE; BINDING ASSAY; BINDING KINETICS; CELL MEDIATED CYTOTOXICITY; CELLS; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY ASSAY; FLOW CYTOMETRY; HODGKIN DISEASE; HUMAN; HUMAN CELL; NATURAL KILLER CELL; SURFACE PLASMON RESONANCE; ANTIBODY COMBINING SITE; ANTIBODY SPECIFICITY; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; PEPTIDE LIBRARY; TUMOR CELL LINE;

ANTIBODIES, BISPECIFIC; ANTIBODY SPECIFICITY; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD30; BINDING SITES, ANTIBODY; CELL LINE, TUMOR; HODGKIN DISEASE; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; PEPTIDE LIBRARY; RECEPTORS, IGG;

EID: 84899744468     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.28591     Document Type: Article

References (34)

1. Mandelboim O, Malik P, Davis DM, Jo CH, Boyson JE, Strominger JL. Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proc Natl Acad Sci U S A 1999; 96:5640-4; PMID:10318937; http://dx.doi.org/10.1073/ pnas.96.10.5640
2. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990; 76:2421-38; PMID:2265240
3. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22:633-40; PMID:11698225; http://dx.doi.org/10.1016/S1471-4906(01)02060-9
4. van de Winkel JG, Capel PJ. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol Today 1993; 14:215-21; PMID:8517920; http://dx.doi.org/10.1016/0167-5699(93)90166-I
5. van Spriel AB, van Ojik HH, van De Winkel JG. Immunotherapeutic perspective for bispecific antibodies. Immunol Today 2000; 21:391-7; PMID:10916142; http://dx.doi.org/10.1016/S0167-5699(00)01659-5
6. Arndt MA, Krauss J, Kipriyanov SM, Pfreundschuh M, Little M. A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors. Blood 1999; 94:2562-8; PMID:10515858
7. McCall AM, Shahied L, Amoroso AR, Horak EM, Simmons HH, Nielson U, Adams GP, Schier R, Marks JD, Weiner LM. Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity. J Immunol 2001; 166:6112-7; PMID:11342630
8. Ory PA, Goldstein IM, Kwoh EE, Clarkson SB. Characterization of polymorphic forms of Fc receptor III on human neutrophils. J Clin Invest 1989; 83:1676-81; PMID:2523415; http://dx.doi.org/10.1172/JCI114067
9. Huizinga TW, Kleijer M, Tetteroo PA, Roos D, von dem Borne AE. Biallelic neutrophil Na-antigen system is associated with a polymorphism on the phosphoinositol-linked Fc gamma receptor III (CD16). Blood 1990; 75:213-7; PMID:2136803
10. Tamm A, Schmidt RE. The binding epitopes of human CD16 (Fc gamma RIII) monoclonal antibodies. Implications for ligand binding. J Immunol 1996; 157:1576-81; PMID:8759741
11. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997; 90:1109-14; PMID:9242542
12. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26:1789-96; PMID:18347005; http://dx.doi.org/10.1200/JCO.2007.14.8957
13. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99:754-8; PMID:11806974; http://dx.doi.org/10.1182/blood.V99.3.754
14. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21:3940-7; PMID:12975461; http://dx.doi.org/10. 1200/JCO.2003.05.013
15. Knackmuss S, Molkenthin V. Antibodies from IgM libraries. In: Little M, editor. Recombinant antibodies for immunotherapy. Cambridge: Cambridge University Press; 2009. p. 66-74.
16. Kipriyanov SM, Moldenhauer G, Schuhmacher J, Cochlovius B, Von der Lieth CW, Matys ER, Little M. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J Mol Biol 1999; 293:41-56; PMID:10512714; http://dx.doi.org/10.1006/jmbi.1999.3156
17. Benhamou M, Bonnerot C, Fridman WH, Daëron M. Molecular heterogeneity of murine mast cell Fc gamma receptors. J Immunol 1990; 144:3071-7; PMID:2139078
18. Schlapschy M, Gruber H, Gresch O, Schäfer C, Renner C, Pfreundschuh M, Skerra A. Gruber H, Gresch O, Schäfer C, Renner C, Pfreundschuh M, Skerra A. Functional humanization of an anti-CD30 Fab fragment for the immunotherapy of Hodgkin's lymphoma using an in vitro evolution approach. Protein Eng Des Sel 2004; 12:847-60; PMID:15708864
19. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 2006; 103:4005-10; PMID:16537476; http://dx.doi.org/10.1073/pnas.0508123103
20. Hombach A, Jung W, Pohl C, Renner C, Sahin U, Schmits R, Wolf J, Kapp U, Diehl V, Pfreundschuh M. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo. Int J Cancer 1993; 55:830-6; PMID:8244580; http://dx.doi.org/10.1002/ijc. 2910550523
21. Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN, Vickers MA. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004; 103:1755-62; PMID:14604957; http://dx.doi.org/10.1182/blood-2003-07-2594
22. Gandhi MK, Lambley E, Duraiswamy J, Dua U, Smith C, Elliott S, Gill D, Marlton P, Seymour J, Khanna R. Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood 2006; 108:2280-9; PMID:16757686; http://dx.doi.org/10.1182/blood-2006-04-015164
23. Küppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009; 9:15-27; PMID:19078975; http://dx.doi.org/10.1038/nrc2542
24. Su CC, Chiu HH, Chang CC, Chen JC, Hsu SM. CD30 is involved in inhibition of T-cell proliferation by Hodgkin's Reed-Sternberg cells. Cancer Res 2004; 64:2148-52; PMID:15026356; http://dx.doi.org/10.1158/0008-5472.CAN-03-1337
25. Hartmann F, Renner C, Jung W, Deisting C, Juwana M, Eichentopf B, Kloft M, Pfreundschuh M. Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Blood 1997; 89:2042-7; PMID:9058726
26. Hartmann F, Renner C, Jung W, da Costa L, Tembrink S, Held G, Sek A, König J, Bauer S, Kloft M, et al. Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines. Clin Cancer Res 2001; 7:1873-81; PMID:11448899
27. Reiners KS, Kessler J, Sauer M, Rothe A, Hansen HP, Reusch U, Hucke C, Köhl U, Dürkop H, Engert A, et al. Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients. Mol Ther 2013; 21:895-903; PMID:23459515; http://dx.doi.org/10.1038/mt.2013.14
28. Le Gall F, Reusch U, Little M, Kipriyanov SM. Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody. Protein Eng Des Sel 2004; 17:357-66; PMID:15126676; http://dx.doi.org/10.1093/protein/gzh039
29. Mandelboim O, Lieberman N, Lev M, Paul L, Arnon TI, Bushkin Y, Davis DM, Strominger JL, Yewdell JW, Porgador A. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 2001; 409:1055-60; PMID:11234016; http://dx.doi.org/10.1038/35059110
30. Kipriyanov SM, Cochlovius B, Schäfer HJ, Moldenhauer G, Bähre A, Le Gall F, Knackmuss S, Little M. Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma. J Immunol 2002; 169:137-44; PMID:12077238
31. Fuss IJ, Kanof ME, Smith PD, Zola H. Isolation of whole mononuclear cells from peripheral blood and cord blood. Curr Protoc Immunol 2009; Chapter 7: Unit7.1.
32. Schodin BA, Kranz DM. Binding affinity and inhibitory properties of a single-chain anti-T cell receptor antibody. J Biol Chem 1993; 268:25722-7; PMID:8245009
33. Engert A, Burrows F, Jung W, Tazzari PL, Stein H, Pfreundschuh M, Diehl V, Thorpe P. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease. Cancer Res 1990; 50:84-8; PMID:2152774
34. Le Gall F, Reusch U, Moldenhauer G, Little M, Kipriyanov SM. Immunosuppressive properties of anti-CD3 single-chain Fv and diabody. J Immunol Methods 2004; 285:111-27; PMID:14871540; http://dx.doi.org/10.1016/j.jim.2003. 11.007